JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
CN104284669A
(zh)
|
2012-02-24 |
2015-01-14 |
弗雷德哈钦森癌症研究中心 |
治疗血红蛋白病的组合物和方法
|
ES2636902T3
(es)
|
2012-05-25 |
2017-10-10 |
The Regents Of The University Of California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
EA039384B1
(ru)
*
|
2012-08-29 |
2022-01-20 |
Сангамо Байосаенсез, Инк. |
Белок "цинковые пальцы" для модулирования экспрессии гена bcl11a и способ модулирования экспрессии глобинового гена
|
CN104955943B
(zh)
|
2012-11-27 |
2018-09-25 |
儿童医疗中心有限公司 |
用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件
|
CN105142669B
(zh)
|
2012-12-06 |
2018-07-03 |
西格马-奥尔德里奇有限责任公司 |
基于crispr的基因组修饰和调控
|
AU2013359199C1
(en)
|
2012-12-12 |
2021-06-17 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
EP4282970A3
(en)
|
2012-12-17 |
2024-01-17 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
EP3620534B1
(en)
|
2013-03-14 |
2021-10-13 |
Caribou Biosciences, Inc. |
Crispr-cas compositions of nucleic acid-targeting nucleic acids
|
CA2907198C
(en)
|
2013-03-15 |
2019-12-10 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
CN115261411A
(zh)
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
CA2910489A1
(en)
|
2013-05-15 |
2014-11-20 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
CA3176690A1
(en)
|
2013-06-04 |
2014-12-11 |
President And Fellows Of Harvard College |
Rna-guided transcriptional regulation
|
US9267135B2
(en)
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
DK3011031T3
(da)
|
2013-06-17 |
2020-12-21 |
Broad Inst Inc |
Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
|
SG11201510286QA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
JP6738729B2
(ja)
|
2013-06-17 |
2020-08-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
JP2016528890A
(ja)
*
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いるゲノム編集の治療用の使用
|
CA2917639C
(en)
|
2013-07-10 |
2024-01-02 |
President And Fellows Of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
US10563225B2
(en)
|
2013-07-26 |
2020-02-18 |
President And Fellows Of Harvard College |
Genome engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
LT3066201T
(lt)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
|
HRP20211706T1
(hr)
|
2013-11-13 |
2022-02-04 |
The Children's Medical Center Corporation |
Nukleazom posredovana regulacija ekspresije gena
|
US20160298096A1
(en)
*
|
2013-11-18 |
2016-10-13 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
KR20160089527A
(ko)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
CA2932475A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
WO2015103153A1
(en)
*
|
2013-12-31 |
2015-07-09 |
The Regents Of The University Of California |
Cas9 crystals and methods of use thereof
|
CN106133141B
(zh)
*
|
2014-01-08 |
2021-08-20 |
哈佛学院董事及会员团体 |
Rna引导的基因驱动
|
EP3105325B1
(en)
|
2014-02-13 |
2019-12-04 |
Takara Bio USA, Inc. |
Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
|
WO2015138510A1
(en)
|
2014-03-10 |
2015-09-17 |
Editas Medicine., Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US20170173083A1
(en)
*
|
2014-03-26 |
2017-06-22 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
|
EP3981876A1
(en)
*
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
WO2015148860A1
(en)
*
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta-thalassemia
|
WO2015164750A2
(en)
|
2014-04-25 |
2015-10-29 |
Children's Medical Center Corporation |
Compositions and methods to treating hemoglobinopathies
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
CN107429241A
(zh)
*
|
2014-08-14 |
2017-12-01 |
北京百奥赛图基因生物技术有限公司 |
Dna敲入系统
|
KR20230053709A
(ko)
|
2014-09-07 |
2023-04-21 |
셀렉타 바이오사이언시즈, 인크. |
항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
|
HUE055583T2
(hu)
*
|
2014-09-16 |
2021-12-28 |
Sangamo Therapeutics Inc |
Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben
|
US10370673B2
(en)
|
2014-09-26 |
2019-08-06 |
Purecircle Sdn Bhd |
Single nucleotide polymorphism (SNP) markers for stevia
|
JP7068821B2
(ja)
|
2014-12-03 |
2022-05-17 |
アジレント・テクノロジーズ・インク |
化学修飾を有するガイドrna
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
EP3247366A4
(en)
*
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
CN114058582A
(zh)
|
2015-01-26 |
2022-02-18 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
WO2016135559A2
(en)
*
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
US20180030438A1
(en)
*
|
2015-02-23 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
EP3280803B1
(en)
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
US10155938B2
(en)
*
|
2015-04-14 |
2018-12-18 |
City Of Hope |
Coexpression of CAS9 and TREX2 for targeted mutagenesis
|
CN104805118A
(zh)
*
|
2015-04-22 |
2015-07-29 |
扬州大学 |
一种苏禽黄鸡胚胎干细胞特定基因进行靶向敲除方法
|
US11845928B2
(en)
*
|
2015-05-04 |
2023-12-19 |
Tsinghua University |
Methods and kits for fragmenting DNA
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
EP3294873B1
(en)
*
|
2015-05-08 |
2020-08-19 |
The Children's Medical Center Corporation |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
US11390884B2
(en)
|
2015-05-11 |
2022-07-19 |
Editas Medicine, Inc. |
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
CN108026545A
(zh)
|
2015-06-17 |
2018-05-11 |
Uab研究基金会 |
用于将功能性多肽引入到血细胞谱系细胞中的crispr/cas9复合物
|
EP3310932B1
(en)
*
|
2015-06-17 |
2023-08-30 |
The UAB Research Foundation |
Crispr/cas9 complex for genomic editing
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
JP6799586B2
(ja)
|
2015-08-28 |
2020-12-16 |
ザ ジェネラル ホスピタル コーポレイション |
遺伝子操作CRISPR−Cas9ヌクレアーゼ
|
US9897378B2
(en)
|
2015-10-08 |
2018-02-20 |
Nyc Designed Inspirations Llc |
Cosmetic makeup sponge/blender container
|
KR20180069898A
(ko)
|
2015-10-23 |
2018-06-25 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 편집제 및 그의 용도
|
ES2908041T3
(es)
*
|
2015-10-27 |
2022-04-27 |
Childrens Hospital Med Ct |
Uso de inhibidores de MAPK para reducir la pérdida de células madre hematopoyéticas durante el cultivo ex vivo y la manipulación genética
|
AU2016349288A1
(en)
|
2015-11-03 |
2018-05-31 |
President And Fellows Of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
US10858628B2
(en)
*
|
2015-11-04 |
2020-12-08 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
EP3371314B1
(en)
|
2015-11-04 |
2023-07-05 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
WO2017077394A2
(en)
*
|
2015-11-04 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
EA201891532A1
(ru)
*
|
2015-12-28 |
2019-01-31 |
Новартис Аг |
Композиции и способы лечения гемоглобинопатий
|
AU2017212713B2
(en)
|
2016-01-27 |
2023-01-19 |
Oncorus, Inc. |
Oncolytic viral vectors and uses thereof
|
US11530253B2
(en)
|
2016-02-25 |
2022-12-20 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
|
JP2019508051A
(ja)
*
|
2016-03-14 |
2019-03-28 |
エディタス・メディシン、インコーポレイテッド |
β異常ヘモグロビン症を治療するためのCRISPR/CAS関連方法および組成物
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
RS65592B1
(sr)
*
|
2016-04-18 |
2024-06-28 |
Vertex Pharma |
Materijali i postupci za lečenje hemoglobinopatija
|
CN116200465A
(zh)
|
2016-04-25 |
2023-06-02 |
哈佛学院董事及会员团体 |
用于原位分子检测的杂交链反应方法
|
WO2017191503A1
(en)
*
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
CA3031785A1
(en)
*
|
2016-07-25 |
2018-02-01 |
Bluebird Bio, Inc. |
Bcl11a homing endonuclease variants, compositions, and methods of use
|
GB2568182A
(en)
|
2016-08-03 |
2019-05-08 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
CN106244555A
(zh)
*
|
2016-08-23 |
2016-12-21 |
广州医科大学附属第三医院 |
一种提高基因打靶的效率的方法及β‑球蛋白基因位点的碱基原位修复方法
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
ES2952525T3
(es)
|
2016-09-08 |
2023-11-02 |
2Seventy Bio Inc |
Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11518981B2
(en)
|
2017-01-27 |
2022-12-06 |
Children's Hospital Medical Center |
Methods of enhancing engraftment activity of hematopoietic stem cells
|
TW201839136A
(zh)
*
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
GB2575930A
(en)
|
2017-03-23 |
2020-01-29 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
US11591589B2
(en)
|
2017-04-21 |
2023-02-28 |
The General Hospital Corporation |
Variants of Cpf1 (Cas12a) with altered PAM specificity
|
WO2018200597A1
(en)
*
|
2017-04-24 |
2018-11-01 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Homology directed repair compositions for the treatment of hemoglobinopathies
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
WO2018218135A1
(en)
|
2017-05-25 |
2018-11-29 |
The Children's Medical Center Corporation |
Bcl11a guide delivery
|
WO2018218166A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
EP3635120A1
(en)
*
|
2017-06-02 |
2020-04-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
JP7249323B2
(ja)
|
2017-07-26 |
2023-03-30 |
オンコラス, インコーポレイテッド |
腫瘍溶解性ウイルスベクター及びその使用
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
WO2019070974A1
(en)
|
2017-10-04 |
2019-04-11 |
Bluebird Bio, Inc. |
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
|
JP7427584B2
(ja)
|
2017-10-13 |
2024-02-05 |
セレクタ バイオサイエンシーズ インコーポレーテッド |
抗ウイルス導入ベクターigm応答を減弱化するための方法および組成物
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
MA50849A
(fr)
*
|
2017-10-26 |
2020-09-02 |
Vertex Pharma |
Substances et procédés pour le traitement d'hémoglobinopathies
|
CN109722414A
(zh)
*
|
2017-10-27 |
2019-05-07 |
博雅辑因(北京)生物科技有限公司 |
一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
|
SG11202005147WA
(en)
*
|
2017-12-05 |
2020-06-29 |
Vertex Pharma |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
MA51788A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes pour traiter des hémoglobinopathies
|
WO2019150196A1
(en)
|
2018-02-05 |
2019-08-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
AU2019225251A1
(en)
|
2018-02-26 |
2020-10-15 |
AnTolRx, Inc. |
Tolerogenic liposomes and methods of use thereof
|
SG11202008956XA
(en)
|
2018-03-14 |
2020-10-29 |
Editas Medicine Inc |
Systems and methods for the treatment of hemoglobinopathies
|
US10968257B2
(en)
|
2018-04-03 |
2021-04-06 |
The Broad Institute, Inc. |
Target recognition motifs and uses thereof
|
US11981892B2
(en)
|
2018-04-16 |
2024-05-14 |
University Of Massachusetts |
Compositions and methods for improved gene editing
|
AU2019260754A1
(en)
*
|
2018-04-27 |
2020-11-26 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
|
WO2020072699A1
(en)
*
|
2018-10-02 |
2020-04-09 |
Exosome Therapeutics, Inc. |
Exosome loaded therapeutics for treating sickle cell disease
|
WO2020113112A1
(en)
*
|
2018-11-29 |
2020-06-04 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
US20220119784A1
(en)
*
|
2018-12-10 |
2022-04-21 |
2Seventy Bio, Inc. |
Homing endonuclease variants
|
CN113544266A
(zh)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
Crispr相关转座酶系统和其使用方法
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
AU2020223060B2
(en)
|
2019-02-13 |
2023-04-13 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
CN113891936A
(zh)
|
2019-03-19 |
2022-01-04 |
布罗德研究所股份有限公司 |
编辑核苷酸序列的方法和组合物
|
CN110042124A
(zh)
*
|
2019-04-25 |
2019-07-23 |
国家卫生健康委科学技术研究所 |
基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用
|
CN111939271A
(zh)
*
|
2019-04-30 |
2020-11-17 |
博雅辑因(北京)生物科技有限公司 |
一种血红蛋白病治疗有效性预测方法
|
KR20220002565A
(ko)
*
|
2019-04-30 |
2022-01-06 |
에디진 인크. |
이상헤모글로빈증 치료의 효과를 예측하는 방법
|
US20200390718A1
(en)
|
2019-05-28 |
2020-12-17 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
WO2020264532A1
(en)
*
|
2019-06-28 |
2020-12-30 |
Asc Therapeutics Inc. |
Methods and compositions for treating thalassemia or sickle cell disease
|
CN115103910A
(zh)
|
2019-10-03 |
2022-09-23 |
工匠开发实验室公司 |
具有工程化的双引导核酸的crispr系统
|
JP2023502626A
(ja)
*
|
2019-11-15 |
2023-01-25 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
ヒト造血幹前駆細胞におけるアルファ-グロビン遺伝子座での標的化組み込み
|
CN112979823B
(zh)
*
|
2019-12-18 |
2022-04-08 |
华东师范大学 |
一种用于治疗和/或预防β血红蛋白病的产品及融合蛋白
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
JP2023526007A
(ja)
*
|
2020-05-13 |
2023-06-20 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
β-ヘモグロビン異常症の処置のための塩基編集アプローチ
|
EP4262850A1
(en)
*
|
2020-12-21 |
2023-10-25 |
2seventy bio, Inc. |
Compositions and methods for site-directed mutagenesis
|
AU2022235341A1
(en)
|
2021-03-12 |
2023-09-21 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
CN113481184A
(zh)
*
|
2021-08-06 |
2021-10-08 |
北京大学 |
融合蛋白以及其使用方法
|
KR20240055811A
(ko)
|
2021-09-10 |
2024-04-29 |
애질런트 테크놀로지스, 인크. |
프라임 편집을 위한 화학적 변형을 갖는 가이드 rna
|
WO2023064367A1
(en)
|
2021-10-12 |
2023-04-20 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
WO2023172624A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
CN114457119B
(zh)
*
|
2022-04-11 |
2022-08-12 |
中吉智药(南京)生物技术有限公司 |
慢病毒载体在制备治疗β-地中海贫血药物中的应用
|
EP4273242A1
(en)
*
|
2022-05-03 |
2023-11-08 |
ETH Zurich |
Crispr-based modification of human hbd gene
|